Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from EBOS Group Limited ( (AU:EBO) ) is now available.
EBOS Group Limited has notified the market of the lapse of 2,598 performance rights, identified under the ASX security code EBOAA. The conditional rights to securities ceased on 20 March 2026 after the specified performance or vesting conditions were not met or became incapable of being satisfied.
The cessation slightly reduces the company’s pool of potential equity issuance tied to executive or employee incentives. This change may marginally affect future dilution outcomes for existing shareholders but does not alter the company’s ordinary share capital or day-to-day operations.
The most recent analyst rating on (AU:EBO) stock is a Buy with a A$30.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited is an Australasian company listed on the ASX that operates in the healthcare and pharmaceutical distribution sector. The group is involved in supplying medical, pharmaceutical and related products and services across the region, serving pharmacies, hospitals and other healthcare providers as a key link in the healthcare supply chain.
Average Trading Volume: 122,704
Technical Sentiment Signal: Sell
Current Market Cap: A$3.78B
Find detailed analytics on EBO stock on TipRanks’ Stock Analysis page.